EHA 2022 | MANIFEST: pelabresib in combination with ruxolitinib in myelofibrosis
John Mascarenhas, MD, The Mount Sinai Hospital, New York, NY, discusses data from the MANIFEST study (NCT02158858), an open-label, Phase II study investigating the safety and efficacy of pelabresib in combination with ruxolitinib in patients with myelofibrosis (MF). In this video, Dr Mascarenhas discusses data from arms 2 and 3 of the study. In arm 2, patients with suboptimal response to ruxolitinib were treated with pelabresib as an add-on to ruxolitinib, and in arm 3, JAK inhibitor-naïve patients were treated with pelabresib in combination with ruxolitinib. The Phase II interim data showed that treatment was well-tolerated in both treatment arms and resulted in splenic and symptoms responses. Based on data from arm 3 of the Phase II study, a randomized, double-blind, active control, Phase III MANIFEST-2 study (NCT04603495) has been initiated. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding paid to Prof. Mascarenhas’ institution from Incyte, Novartis, Roche, BMS, Celgene, CTI Bio, Merck, PharmaEssentia, Abbvie, Kartos, Geron and consulting fees from Incyte, Celgene, BMS, Constellation, CTI Bio, Geron, Abbvie, Kartos, Novartis, Roche, Imago, Karyopharm, Galecto and PharmaEssentia.
